Newron Pharmaceuticals S.p.A. (SWX: NWRN)

Market Cap	161.81M
Revenue (ttm)	8.43M
Net Income (ttm)	-15.10M
Shares Out	19.06M
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	12.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,435
Open	8.50
Previous Close	8.49
Day's Range	8.36 - 8.74
52-Week Range	4.09 - 11.20
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2024

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schiz...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: NWRN

Financial Performance

In 2023, Leclanché's revenue was 17.20 million, a decrease of -4.27% compared to the previous year's 17.97 million. Losses were -67.53 million, -21.06% less than in 2022.

Financial numbers in EUR